Pfizer

Pfizer Tax Expense

The Income Tax Expense of Pfizer (PFE) as of Oct 26, 2026 is -266.00 M USD. In the previous year, Income Tax Expense was -28.00 M USD — a change of 850.00% (lower).

Tax Expense

-266.00 MUSD

YoY

850.00%

Last updated:

Income Tax Expense of Pfizer is 2025 -266.00 M USD. Income Tax Expense of Pfizer was 2024 -28.00 M USD. It decreases by 850.00% lower compared to the previous year.

The Pfizer Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
706.00 M USD
Jan 1, 2019
618.00 M USD
Jan 1, 2020
370.00 M USD
Jan 1, 2021
1.85 B USD
Jan 1, 2022
3.33 B USD
Jan 1, 2023
-1.11 B USD
Jan 1, 2024
-28.00 M USD
Jan 1, 2025
-266.00 M USD
The Pfizer Tax Expense history
YEARTax ExpenseYoY
-266.00 MUSD+850.00%
-28.00 MUSD-97.49%
-1.11 BUSD-133.47%
3.33 BUSD+79.70%
1.85 BUSD+400.54%
370.00 MUSD-40.13%
618.00 MUSD-12.46%
706.00 MUSD-107.80%
-9.05 BUSD-906.42%
1.12 BUSD-43.62%
1.99 BUSD-36.24%
3.12 BUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pfizer Stock analysis

What does Pfizer do? Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives. Pfizer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pfizer stock

Income Tax Expense of Pfizer is -266.00 M USD in 2025.

Income Tax Expense of Pfizer changed from -28.00 M USD to -266.00 M USD, representing a 850.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Pfizer since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Pfizer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pfizer

All Key Metrics — Pfizer